Table 1.
Characteristics of the study patients with triple-negative breast cancer who received neoadjuvant systemic therapy.
| Characteristic | Value | p-Value | ||
|---|---|---|---|---|
| Age, years | Total (N = 100) | pCR (N = 49) | Non-pCR (N = 51) | 0.893 |
| Mean (SD) | 47.9 (10.8) | 47.5 (10.5) | 48.3 (11.2) | |
| Median (range) | 48 (23–77) | 48 (23–66) | 48 (31–77) | |
| Longest tumor diameter, cm | ||||
| Mean (SD) | 3.4 (1.6) | 3.2 (1.8) | 3.6 (1.5) | N/A |
| Median (range) | 2.8 (1.2–9.6) | 2.7 (1.2–9.6) | 2.9 (1.6–7.9) | |
| Histologic type, n (%) | 0.503 | |||
| Invasive ductal | 87 (87) | 45 (92) | 42 (82) | |
| Metaplastic | 10 (10) | 3 (6) | 7 (14) | |
| Poorly differentiated carcinoma | 1 (1) | 1 (2) | 0 | |
| Apocrine | 1 (1) | 0 | 1 (2) | |
| Invasive mixed ductal/lobular | 1 (1) | 0 | 1 (2) | |
| T category, n (%) | 0.130 | |||
| T1 | 15 (15) | 11 (23) | 4 (8) | |
| T2 | 63 (63) | 30 (61) | 33 (65) | |
| T3 | 16 (16) | 6 (12) | 10 (19) | |
| T4 | 6 (6) | 2 (4) | 4 (8) | |
| N category, n (%) | 0.052 | |||
| N0 | 64 (64) | 36 (74) | 28 (55) | |
| N1 | 20 (20) | 6 (12) | 14 (27) | |
| N2 | 4 (4) | 1 (2) | 2 (4) | |
| N3 | 12 (12) | 6 (12) | 7 (14) | |
| Overall clinical stage, n (%) | 0.141 | |||
| I | 10 (10) | 7 (14) | 3 (6) | |
| II | 68 (68) | 34 (70) | 34 (67) | |
| III | 22 (22) | 8 (16) | 14 (27) | |
| Type of surgery, n (%) | N/A | |||
| Total mastectomy | 45 (45) | 21 (43) | 24 (47) | |
| Breast-conserving surgery | 55 (55) | 28 (57) | 27 (53) | |
SD, standard deviation; pCR, pathologic complete response.